164 related articles for article (PubMed ID: 22552360)
1. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Shitara K; Sawaki A; Matsuo K; Kondo C; Takahari D; Ura T; Tajika M; Niwa Y; Muro K
Int J Clin Oncol; 2013 Jun; 18(3):539-46. PubMed ID: 22552360
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
[TBL] [Abstract][Full Text] [Related]
3. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
4. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Yamaguchi K; Sawaki A; Doi T; Satoh T; Yamada Y; Omuro Y; Nishina T; Boku N; Chin K; Hamamoto Y; Takiuchi H; Komatsu Y; Saji S; Koizumi W; Miyata Y; Sato A; Baba E; Tamura T; Abe T; Ohtsu A
Gastric Cancer; 2013 Apr; 16(2):175-82. PubMed ID: 22782463
[TBL] [Abstract][Full Text] [Related]
6. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Shitara K; Mizota A; Matsuo K; Sato Y; Kondo C; Takahari D; Ura T; Tajika M; Muro K
Gastric Cancer; 2013 Jan; 16(1):48-55. PubMed ID: 22362376
[TBL] [Abstract][Full Text] [Related]
7. Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H; Fujitani K; Matsuyama J; Akamaru Y; Tamura S; Endo S; Kimura Y; Makari Y; Tamura T; Sugimoto N; Sakai D; Tsujinaka T; Goto M; Kurokawa Y; Shimokawa T; Satoh T;
Int J Clin Oncol; 2020 Sep; 25(9):1635-1643. PubMed ID: 32494981
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
Okita A; Imai H; Takahashi M; Takahashi H; Umegaki S; Kawamura Y; Hiraide S; Ouchi K; Sato Y; Okada Y; Komine K; Saijo K; Takahashi S; Takahashi M; Shirota H; Ohori H; Gamoh M; Ishioka C
Tohoku J Exp Med; 2018 Jun; 245(2):123-129. PubMed ID: 29937450
[TBL] [Abstract][Full Text] [Related]
10. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
[TBL] [Abstract][Full Text] [Related]
11. Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.
Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Fukutomi A; Todaka A; Taniguchi H; Onozawa Y; Taku K
Int J Clin Oncol; 2013 Feb; 18(1):10-6. PubMed ID: 22020563
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
[TBL] [Abstract][Full Text] [Related]
13. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
Zhu B; Wu JR; Zhou XP
Medicine (Baltimore); 2015 Aug; 94(34):e1428. PubMed ID: 26313797
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
Kang YK; Kang WK; Shin DB; Chen J; Xiong J; Wang J; Lichinitser M; Guan Z; Khasanov R; Zheng L; Philco-Salas M; Suarez T; Santamaria J; Forster G; McCloud PI
Ann Oncol; 2009 Apr; 20(4):666-73. PubMed ID: 19153121
[TBL] [Abstract][Full Text] [Related]
18. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Satoh T; Yamada Y; Muro K; Hayashi H; Shimada Y; Takahari D; Taku K; Nakajima TE; Shi X; Brown KH; Boku N
Cancer Chemother Pharmacol; 2012 Feb; 69(2):439-46. PubMed ID: 21853311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
